{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:16:56Z","timestamp":1791227816994,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T00:00:00Z","timestamp":1638230400000},"content-version":"vor","delay-in-days":2661,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Chronic myeloid leukemia (CML) is initiated and maintained by the tyrosine kinase BCR-ABL which activates a number of signal transduction pathways, including PI3K\/AKT signaling and consequently inactivates FOXO transcription factors. ABL-specific tyrosine kinase inhibitors (TKIs) induce minimal apoptosis in CML progenitor cells, yet exert potent antiproliferative effects, through as yet poorly understood mechanisms. Here, we demonstrate that in CD34+ CML cells, FOXO1 and 3a are inactivated and relocalized to the cytoplasm by BCR-ABL activity. TKIs caused a decrease in phosphorylation of FOXOs, leading to their relocalization from cytoplasm (inactive) to nucleus (active), where they modulated the expression of key FOXO target genes, such as Cyclin D1, ATM, CDKN1C, and BCL6 and induced G1 arrest. Activation of FOXO1 and 3a and a decreased expression of their target gene Cyclin D1 were also observed after 6 days of in vivo treatment with dasatinib in a CML transgenic mouse model. The over-expression of FOXO3a in CML cells combined with TKIs to reduce proliferation, with similar results seen for inhibitors of PI3K\/AKT\/mTOR signaling. While stable expression of an active FOXO3a mutant induced a similar level of quiescence to TKIs alone, shRNA-mediated knockdown of FOXO3a drove CML cells into cell cycle and potentiated TKI-induced apoptosis. These data demonstrate that TKI-induced G1 arrest in CML cells is mediated through inhibition of the PI3K\/AKT pathway and reactivation of FOXOs. This enhanced understanding of TKI activity and induced progenitor cell quiescence suggests that new therapeutic strategies for CML should focus on manipulation of this signaling network. Stem Cells \u00a02014;32:2324\u20132337<\/jats:p>","DOI":"10.1002\/stem.1748","type":"journal-article","created":{"date-parts":[[2014,5,8]],"date-time":"2014-05-08T08:28:06Z","timestamp":1399537686000},"page":"2324-2337","source":"Crossref","is-referenced-by-count":86,"title":["The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors"],"prefix":"10.1093","volume":"32","author":[{"given":"Francesca","family":"Pellicano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary T.","family":"Scott","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, College of Medical, Veterinary & Life Sciences Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Vignir","family":"Helgason","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, College of Medical, Veterinary & Life Sciences Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E. M.","family":"Hopcroft","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, College of Medical, Veterinary & Life Sciences Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine K.","family":"Allan","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, College of Medical, Veterinary & Life Sciences Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Aspinall-O\u2019Dea","sequence":"additional","affiliation":[{"name":"Stem Cell and Leukaemia Proteomics Laboratory, School of Cancer and Enabling Sciences, Manchester Academic Health Science Centre The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhairi","family":"Copland","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, College of Medical, Veterinary & Life Sciences Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Pierce","sequence":"additional","affiliation":[{"name":"Stem Cell and Leukaemia Proteomics Laboratory, School of Cancer and Enabling Sciences, Manchester Academic Health Science Centre The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J. P.","family":"Huntly","sequence":"additional","affiliation":[{"name":"Department of Haematology and Wellcome Trust Stem Cell Institute University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Whetton","sequence":"additional","affiliation":[{"name":"Stem Cell and Leukaemia Proteomics Laboratory, School of Cancer and Enabling Sciences, Manchester Academic Health Science Centre The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, College of Medical, Veterinary & Life Sciences Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,8,18]]},"reference":[{"key":"2022011201141188500_stem1748-bib-0001","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"2022011201141188500_stem1748-bib-0002","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"2022011201141188500_stem1748-bib-0003","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0004","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0005","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"2022011201141188500_stem1748-bib-0006","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0007","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"2022011201141188500_stem1748-bib-0008","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0009","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2011","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0010","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest"},{"key":"2022011201141188500_stem1748-bib-0011","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0012","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0013","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0014","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1038\/onc.2008.29","article-title":"A brief introduction to FOXOlogy","volume":"27","author":"Burgering","year":"2008","journal-title":"Oncogene"},{"key":"2022011201141188500_stem1748-bib-0015","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.stem.2007.07.017","article-title":"FoxO transcription factors and stem cell homeostasis: Insights from the hematopoietic system","volume":"1","author":"Tothova","year":"2007","journal-title":"Cell Stem Cell"},{"key":"2022011201141188500_stem1748-bib-0016","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nature08734","article-title":"TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia","volume":"463","author":"Naka","year":"2010","journal-title":"Nature"},{"key":"2022011201141188500_stem1748-bib-0017","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/nature09883","article-title":"BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition","volume":"473","author":"Duy","year":"2011","journal-title":"Nature"},{"key":"2022011201141188500_stem1748-bib-0018","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1084\/jem.20110304","article-title":"BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia","volume":"208","author":"Hurtz","year":"2011","journal-title":"J Exp Med"},{"key":"2022011201141188500_stem1748-bib-0019","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1084\/jem.20112087","article-title":"Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks","volume":"208","author":"Pellicano","year":"2011","journal-title":"J Exp Med"},{"key":"2022011201141188500_stem1748-bib-0020","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell"},{"key":"2022011201141188500_stem1748-bib-0021","doi-asserted-by":"crossref","first-page":"6411","DOI":"10.1074\/jbc.M211562200","article-title":"A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells","volume":"278","author":"Komatsu","year":"2003","journal-title":"J Biol Chem"},{"key":"2022011201141188500_stem1748-bib-0022","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1111\/j.1349-7006.2007.00623.x","article-title":"Active FKHRL1 overcomes imatinib resistance in chronic myelogenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand","volume":"98","author":"Kikuchi","year":"2007","journal-title":"Cancer Sci"},{"key":"2022011201141188500_stem1748-bib-0023","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1073\/pnas.0731871100","article-title":"Cytokines and BCR-ABL mediate suppression of TRAIL-induced apoptosis through inhibition of forkhead FOXO3a transcription factor","volume":"100","author":"Ghaffari","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022011201141188500_stem1748-bib-0024","doi-asserted-by":"crossref","first-page":"10058","DOI":"10.1128\/MCB.24.22.10058-10071.2004","article-title":"FoxO3a and BCR-ABL regulate cyclin D2 transcription through a STAT5\/BCL6-dependent mechanism","volume":"24","author":"Fernandez de Mattos","year":"2004","journal-title":"Mol Cell Biol"},{"key":"2022011201141188500_stem1748-bib-0025","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1074\/jbc.M606669200","article-title":"FOXO3a induces differentiation of Bcr-Abl-transformed cells through transcriptional down-regulation of Id1","volume":"282","author":"Birkenkamp","year":"2007","journal-title":"J Biol Chem"},{"key":"2022011201141188500_stem1748-bib-0026","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.onc.1208421","article-title":"Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells","volume":"24","author":"Essafi","year":"2005","journal-title":"Oncogene"},{"key":"2022011201141188500_stem1748-bib-0027","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1182\/blood-2003-12-4369","article-title":"Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis","volume":"105","author":"Koschmieder","year":"2005","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0028","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1182\/blood-2009-05-219550","article-title":"BMS-214662 induces mitochondrial apoptosis in chronic myeloid leukemia (CML) stem\/progenitor cells, including CD34+38- cells, through activation of protein kinase Cbeta","volume":"114","author":"Pellicano","year":"2009","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0029","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1038\/leu.2011.67","article-title":"The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem\/progenitor cells","volume":"25","author":"Pellicano","year":"2011","journal-title":"Leukemia"},{"key":"2022011201141188500_stem1748-bib-0030","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature04809","article-title":"Identification of a tumour suppressor network opposing nuclear Akt function","volume":"441","author":"Trotman","year":"2006","journal-title":"Nature"},{"key":"2022011201141188500_stem1748-bib-0031","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.febslet.2004.07.055","article-title":"Rank products: A simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments","volume":"573","author":"Breitling","year":"2004","journal-title":"FEBS Lett"},{"key":"2022011201141188500_stem1748-bib-0032","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/leu.2008.337","article-title":"Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy","volume":"23","author":"Bruennert","year":"2009","journal-title":"Leukemia"},{"key":"2022011201141188500_stem1748-bib-0033","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.stem.2007.02.001","article-title":"Foxo3a is essential for maintenance of the hematopoietic stem cell pool","volume":"1","author":"Miyamoto","year":"2007","journal-title":"Cell Stem Cell"},{"key":"2022011201141188500_stem1748-bib-0034","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent anti-proliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"2022011201141188500_stem1748-bib-0035","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/nature07016","article-title":"PML targeting eradicates quiescent leukaemia-initiating cells","volume":"453","author":"Ito","year":"2008","journal-title":"Nature"},{"key":"2022011201141188500_stem1748-bib-0036","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.stem.2011.06.014","article-title":"p57 is required for quiescence and maintenance of adult hematopoietic stem cells","volume":"9","author":"Matsumoto","year":"2011","journal-title":"Cell Stem Cell"},{"key":"2022011201141188500_stem1748-bib-0037","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.molcel.2006.03.029","article-title":"Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt\/PKB","volume":"22","author":"Sarbassov","year":"2006","journal-title":"Mol Cell"},{"key":"2022011201141188500_stem1748-bib-0038","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia\u2014Advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N Engl J Med"},{"key":"2022011201141188500_stem1748-bib-0039","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.cell.2007.01.003","article-title":"FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress","volume":"128","author":"Tothova","year":"2007","journal-title":"Cell"}],"container-title":["Stem Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fstem.1748","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/stem.1748","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/stem.1748","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/32\/9\/2324\/41984227\/stmcls_32_9_2324.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stmcls\/article-pdf\/32\/9\/2324\/41984227\/stmcls_32_9_2324.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T02:53:27Z","timestamp":1642560807000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stmcls\/article\/32\/9\/2324-2337\/6422992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,18]]},"references-count":39,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2014,8,18]]},"published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.1002\/stem.1748","relation":{},"ISSN":["1066-5099","1549-4918"],"issn-type":[{"value":"1066-5099","type":"print"},{"value":"1549-4918","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,9,1]]},"published":{"date-parts":[[2014,8,18]]}}}